Study: NCT02858401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally once every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.